dr. kahl discusses the potential of frontline ibrutinib in mcl
Published 6 years ago • 101 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
0:56
dr. kahl on the potential of car t-cell therapy in mcl
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
1:35
dr. kahl on frontline therapy selection in cll
-
1:43
the role of targeted therapies in the frontline treatment of mantle cell lymphoma
-
1:43
dr. kahl on ibrutinib in cll
-
1:04
ibrutnib in older patients with mantle cell lymphoma
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
2:05
dr. kahl on the impact of venetoclax in chronic lymphocytic leukemia
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
1:05
dr. kahl on the current treatment landscape in relapsed/refractory inhl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
4:07
author voices: brad kahl, md